Anti-NAMPT mAb

IP - 1-2 ug/sample

Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B-cell colony-enhancing factor, is the rate-limiting enzyme that converts nicotinamide to nicotinamide mononucleotide (NMN) from nicotinamide in the salvage pathway of NAD+ biosynthesis in mammals. Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) converts NMN to NAD+. The expression of NAMPT is upregulated during activation of immune cells such as monocytes, macrophages, dendritic cells, T and B cells, as well as in amniotic epithelial cells upon stimulation with several inflammatory cytokines. NAMPT-specific inhibitor, FK866 was found to deplete intracellular NAD content, resulting in apoptotic cell death in many cancer cell lines without any DNA damaging effect. Recently, Nakahata K et al, demonstrated that NAMPT is required to modulate circadian gene expression and circadian oscillation of NAD+.

1.0 mg/mL

Supplied in 20mM phosphatase buffer (pH 7.5), 300mM NaCl, 50% glycerol.

Human: 10135 Mouse: 59027

His-tagged human NAMPT

50-55 kDa

1 year

The antibody is produced by immunizing mice with a His-tagged- NAMPT, corresponding full length of human NAMPT, expressed in E. coli. IgG is purified by protein A-Sepharose chromatography.

NAMPT